Last 12 months
Inside the activity.
0 purchase rows · 16 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 2 |
| Dec 2025 | 0 | 2 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 2 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 4 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 08, 2017 Filed Feb 9, 2017 14:48 UTC |
Gull Global Ltd10% owner
|
SaleCommon Stock | 20,000 | $55.87 | $1,117,344.00 |
DisclosureSEC source: 0001179110-17-002012 · edgar.xml · nonDerivative · entry 1 Gull Global Ltd · CIK 0001636301 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,558,220 F1 · shares: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2015. F3 · price: Weighted average price. Price range in multiple transactions was $54.60 to $58.10, inclusive. The reporting person undertakes to provide USANA Health Sciences, Inc., any security holder thereof or the staff at the Securities and Exchange Commission information regarding the number of shares sold at each price within the ranges set forth. Read SEC document |
| January 11, 2017 Filed Jan 12, 2017 15:53 UTC |
Gull Global Ltd10% owner
|
SaleCommon Stock | 20,000 | $61.04 | $1,220,836.00 |
DisclosureSEC source: 0001179110-17-000917 · edgar.xml · nonDerivative · entry 1 Gull Global Ltd · CIK 0001636301 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,578,220 F1 · shares: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2015. F3 · price: Weighted average price. Price range in multiple transactions was $60.35 to $62.00, inclusive. The reporting person undertakes to provide USANA Health Sciences, Inc., any security holder thereof or the staff at the Securities and Exchange Commission information regarding the number of shares sold at each price within the ranges set forth. Read SEC document |
| January 11, 2017 Filed Jan 12, 2017 15:52 UTC |
WENTZ MYRON WDirector
|
SaleCommon Stock | 20,000 | $61.04 | $1,220,836.00 |
DisclosureSEC source: 0001179110-17-000916 · edgar.xml · nonDerivative · entry 1 WENTZ MYRON W · CIK 0001203301 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares owned of record by Gull Global Limited Disclosed balance after: 12,578,220 F1 · shares: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2015. F3 · price: Weighted average price. Price range in multiple transactions was $60.35 to $62.00, inclusive. The reporting person undertakes to provide USANA Health Sciences, Inc., any security holder thereof or the staff at the Securities and Exchange Commission information regarding the number of shares sold at each price within the ranges set forth. F1 · ownership.nature: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. Read SEC document |
| December 16, 2016 Filed Dec 19, 2016 22:29 UTC |
Noot WalterChief Information Officer
|
GrantStock-Settled Stock Appreciation Right · Derivative | 80,000 | $0.00 Strike: $62.20 | $0.00 |
DisclosureSEC source: 0001179110-16-033216 · edgar.xml · derivative · entry 1 Noot Walter · CIK 0001691991 · Chief Information Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2022-07-16 F1 · derivative.exercise_date: Stock-Settled Stock Appreciation Rights granted vest at 20% per year for five years, commencing on the first anniversary of the grant date. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 19:19 UTC |
Gull Global Ltd10% owner
|
SaleCommon Stock | 20,000 | $61.41 | $1,228,158.00 |
DisclosureSEC source: 0001179110-16-033092 · edgar.xml · nonDerivative · entry 1 Gull Global Ltd · CIK 0001636301 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,598,220 F1 · shares: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2015. F4 · shares: Sales reported have been adjusted pursuant to a two-for-one (2-1) forward stock split, which was distributed and paid on November 22, 2016. F3 · price: Weighted average price. Price range in multiple transactions was $60.825 to $62.75, inclusive. The reporting person undertakes to provide USANA Health Sciences, Inc., any security holder thereof or the staff at the Securities and Exchange Commission information regarding the number of shares sold at each price within the ranges set forth. F4 · balance_after: Sales reported have been adjusted pursuant to a two-for-one (2-1) forward stock split, which was distributed and paid on November 22, 2016. Read SEC document |
| December 14, 2016 Filed Dec 16, 2016 19:17 UTC |
WENTZ MYRON WDirector
|
SaleCommon Stock | 20,000 | $61.41 | $1,228,158.00 |
DisclosureSEC source: 0001179110-16-033091 · edgar.xml · nonDerivative · entry 1 WENTZ MYRON W · CIK 0001203301 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares owned of record by Gull Global Limited Disclosed balance after: 12,598,220 F1 · shares: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2015. F4 · shares: Sales reported have been adjusted pursuant to a two-for-one (2-1) forward stock split, which was distributed and paid on November 22, 2016. F3 · price: Weighted average price. Price range in multiple transactions was $60.825 to $62.75, inclusive. The reporting person undertakes to provide USANA Health Sciences, Inc., any security holder thereof or the staff at the Securities and Exchange Commission information regarding the number of shares sold at each price within the ranges set forth. F4 · balance_after: Sales reported have been adjusted pursuant to a two-for-one (2-1) forward stock split, which was distributed and paid on November 22, 2016. F1 · ownership.nature: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 16:41 UTC |
WENTZ MYRON WDirector
|
SaleCommon Stock | 10,000 | $123.99 | $1,239,940.00 |
DisclosureSEC source: 0001179110-16-031389 · edgar.xml · nonDerivative · entry 1 WENTZ MYRON W · CIK 0001203301 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares owned of record by Gull Global Limited Disclosed balance after: 6,309,110 F1 · shares: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2015. F3 · price: Weighted average price. Price range in multiple transactions was $120.925 to $125.55, inclusive. The reporting person undertakes to provide USANA Health Sciences, Inc., any security holder thereof or the staff at the Securities and Exchange Commission information regarding the number of shares sold at each price within the ranges set forth. F1 · ownership.nature: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. Read SEC document |
| November 09, 2016 Filed Nov 10, 2016 16:40 UTC |
Gull Global Ltd10% owner
|
SaleCommon Stock | 10,000 | $123.99 | $1,239,940.00 |
DisclosureSEC source: 0001179110-16-031388 · edgar.xml · nonDerivative · entry 1 Gull Global Ltd · CIK 0001636301 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,309,110 F1 · shares: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2015. F3 · price: Weighted average price. Price range in multiple transactions was $120.925 to $125.55, inclusive. The reporting person undertakes to provide USANA Health Sciences, Inc., any security holder thereof or the staff at the Securities and Exchange Commission information regarding the number of shares sold at each price within the ranges set forth. Read SEC document |
| October 12, 2016 Filed Oct 13, 2016 13:10 UTC |
WENTZ MYRON WDirector
|
SaleCommon Stock | 10,000 | $146.35 | $1,463,495.00 |
DisclosureSEC source: 0001179110-16-030672 · edgar.xml · nonDerivative · entry 1 WENTZ MYRON W · CIK 0001203301 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares owned of record by Gull Global Limited Disclosed balance after: 6,319,110 F1 · shares: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2015. F3 · price: Weighted average price. Price range in multiple transactions was $145.65 to $147.25, inclusive. The reporting person undertakes to provide USANA Health Sciences, Inc., any security holder thereof or the staff at the Securities and Exchange Commission information regarding the number of shares sold at each price within the ranges set forth. F1 · ownership.nature: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. Read SEC document |
| October 12, 2016 Filed Oct 13, 2016 13:09 UTC |
Gull Global Ltd10% owner
|
SaleCommon Stock | 10,000 | $146.35 | $1,463,495.00 |
DisclosureSEC source: 0001179110-16-030671 · edgar.xml · nonDerivative · entry 1 Gull Global Ltd · CIK 0001636301 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,319,110 F1 · shares: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2015. F3 · price: Weighted average price. Price range in multiple transactions was $145.65 to $147.25, inclusive. The reporting person undertakes to provide USANA Health Sciences, Inc., any security holder thereof or the staff at the Securities and Exchange Commission information regarding the number of shares sold at each price within the ranges set forth. Read SEC document |
| September 14, 2016 Filed Sep 15, 2016 17:57 UTC |
WENTZ MYRON WDirector
|
SaleCommon Stock | 10,000 | $134.67 | $1,346,736.00 |
DisclosureSEC source: 0001179110-16-029683 · edgar.xml · nonDerivative · entry 1 WENTZ MYRON W · CIK 0001203301 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Shares owned of record by Gull Global Limited Disclosed balance after: 6,329,110 F1 · shares: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2015. F3 · price: Weighted average price. Price range in multiple transactions was $134.08 to $135.13, inclusive. The reporting person undertakes to provide USANA Health Sciences, Inc., any security holder thereof or the staff at the Securities and Exchange Commission information regarding the number of shares sold at each price within the ranges set forth. F1 · ownership.nature: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. Read SEC document |
| September 14, 2016 Filed Sep 15, 2016 17:57 UTC |
Gull Global Ltd10% owner
|
SaleCommon Stock | 10,000 | $134.67 | $1,346,736.00 |
DisclosureSEC source: 0001179110-16-029682 · edgar.xml · nonDerivative · entry 1 Gull Global Ltd · CIK 0001636301 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,329,110 F1 · shares: The holder of record of the shares of Common Stock disposed is Gull Global Limited, an entity wholly indirectly owned and controlled by Dr. Myron W. Wentz. F2 · shares: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2015. F3 · price: Weighted average price. Price range in multiple transactions was $134.08 to $135.13, inclusive. The reporting person undertakes to provide USANA Health Sciences, Inc., any security holder thereof or the staff at the Securities and Exchange Commission information regarding the number of shares sold at each price within the ranges set forth. Read SEC document |
| September 08, 2016 Filed Sep 9, 2016 16:29 UTC |
Woo DeborahPresident of Asia
|
Exercise / conversionStock Settled Stock Appreciation Rights · Derivative | 2,000 | $0.00 Strike: $57.62 | $0.00 |
DisclosureSEC source: 0001179110-16-029477 · edgar.xml · derivative · entry 3 Woo Deborah · CIK 0001441748 · President of Asia 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Stock · 2,000 shares Expires 2018-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 08, 2016 Filed Sep 9, 2016 16:29 UTC |
Woo DeborahPresident of Asia
|
SaleCommon Stock | 1,058 | $140.00 | $148,120.00 |
DisclosureSEC source: 0001179110-16-029477 · edgar.xml · nonDerivative · entry 2 Woo Deborah · CIK 0001441748 · President of Asia 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,479 Read SEC document |
| September 08, 2016 Filed Sep 9, 2016 16:29 UTC |
Woo DeborahPresident of Asia
|
Exercise / conversionCommon Stock | 1,176 | $57.62 | $67,761.12 |
DisclosureSEC source: 0001179110-16-029477 · edgar.xml · nonDerivative · entry 1 Woo Deborah · CIK 0001441748 · President of Asia 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The shares acquired resulted from reporting person's settlement of the stock-settled stock appreciation rights in Table-II. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.